Vagus Nerve Stimulation Market

The Vagus Nerve Stimulation Market is valued at USD 586.8 Mn in 2026 and is projected to reach USD 963.9 Mn, growing at a CAGR of 6% by 2033.

Increasing Prevalence of Neurological Illnesses Will Boost Vagus Nerve Stimulation Market

The growing geriatric population, the emergence of technologically advanced products, the rising demand for products as an add-on therapy, the rising prevalence of chronic diseases like migraine, and epilepsy, and the existence of significant unmet medical needs in these disease segments are some of the major factors propelling the vagus nerve stimulation market growth. Other factors driving the expansion of the vagus nerve stimulation (VNS) sector include the increasing prevalence of neurological and lifestyle-related illnesses, outside investment for R&D, and demand for minimally invasive surgeries. The main growth factors for the global vagus nerve stimulation market are the rising prevalence of neurological illnesses like epilepsy, depression, and migraine and the increased use of minimally invasive neurosurgery treatments. Since epilepsy is a chronic condition, most epileptic patients control their seizures with medication and dietary restrictions. However, in roughly 30% of cases, drugs cannot stop seizures, forcing patients to turn to VNS therapy. Epileptic seizures are 50% less likely to occur while a VNS device is used. Over the next six years, the market will likely be driven primarily by two factors: the great efficacy of these devices in treating epilepsy and their application in treating disorders such as chronic depression.

The high prevalence of depression brought on by lifestyle choices, such as stress brought on by work pressure, and the rising incidence of treatment-resistant depression globally are some other key factors influencing the market expansion. Nearly 30% of patients, on average, are thought to be resistant to therapy, according to WHO estimates. When a patient with depression does not improve after receiving normal treatment, VNS therapy is thought to be the most effective option. As a result, during the projected period, it is anticipated that the rising prevalence of chronic illnesses, such as migraine and epilepsy, will aid in the vagus nerve stimulation market expansion. Vagus nerve stimulators are also expected to benefit from technological developments, opening up new market potential.

Vagus Nerve Stimulation Market: COVID-19 Impact

The global healthcare system was significantly hit by the COVID-19 pandemic, with the United States being one of the worst-affected nations. Due to a short pause in research activity in this area and a low patient intake in hospitals and diagnostic facilities, the pandemic had a detrimental effect on the vagus nerve stimulation market growth. Manufacturers are taking many strategic actions to recover from COVID-19. The players are engaging in many R&D initiatives, product launches, and strategic alliances to advance the technology and test results used in the pharmacogenetics testing.

Introduction of Non-invasive Devices to Drive Vagus Nerve Stimulation Market Growth

The vagus nerve governs particular brain activities and regions, and vagus nerve stimulation is a method for electrically stimulating this nerve. Leads are attached to the vagus nerve, and traditional vagus nerve stimulation devices, which deliver electrical stimulation as necessary, are implanted in the patient's body. Small-sized implantable VNS devices have just entered the vagus nerve stimulation market due to technological advancements and increased consumer demand for cutting-edge technology. These tiny implantable devices have many clinical advantages for patients and medical professionals. It is projected that the introduction of novel gadgets will fuel the market expansion during the forecast period. Non-invasive vagus nerve stimulation (nVNS) devices have begun to appear on the market due to players' constant focus on innovation and introducing new goods. For instance, electroCore Inc.'s gammaCore (nVNS), a non-invasive vagus nerve stimulation device, was authorized by the US FDA in late 2019. The clinical advantages of this technology include avoiding surgical implant operations and changing the implanted devices, which eliminates any potential side effects.

Growth in Epilepsy, and Other Conditions Will Drive Vagus Nerve Stimulation Market

With a much higher frequency in developing nations, epilepsy is one of the most prevalent neurological disorders worldwide. Around 50 million people worldwide are thought to have epilepsy, according to the Epilepsy Foundation of America and the World Health Organization (WHO). One of the nations with the highest percentage of the population suffering from the illness was Brazil, followed by China, India, and Brazil. An estimated 18 million Americans, according to the National Institute of Mental Health (NIMH), were depressed in some way. It was further enhanced by the rising prevalence of treatment-resistant depression and the rising number of patients affected by the disease, which increased the demand for electrical stimulation devices, particularly VNS, to treat these conditions. The adoption of these devices and the vagus nerve stimulation market expansion are further anticipated to be fueled by the aspects mentioned earlier in combination with the launch of non-invasive VNS devices by industry players.

Vagus Nerve Stimulation Market Witnesses Limited Adoption of VNS Device Due to High Surgical Implantation Costs, and Lower Treatment Rates in Developing Nations

Despite the rising frequency of epilepsy, depression, and other chronic illnesses worldwide and in emerging economies, several difficulties are preventing the widespread use of VNS devices. Lower rates of neurological disorder drugs and other treatments in developing nations are one of the main issues impeding vagus nerve stimulation market expansion. A small number of patients are receiving treatment, and a sizable majority of them still prefer traditional medications to address these problems. It significantly reduces the proportion of patients who favor VNS therapy. Additional issues limiting market growth include the high cost of implantable VNS devices, the high cost of surgery, and the absence of authorized non-invasive VNS devices.

Implantable VNS Device Category Spearheads Vagus Nerve Stimulation Market with Rise in Patients with Epilepsy

The implantable VNS device category held the largest vagus nerve stimulation market share. It is anticipated that it will continue to rule the market during the forecast period due to a rise in patients with epilepsy, depression, and various headache conditions. It is more successful in treating the condition with implanted VNS devices since they are designed to work directly on the painful area and change nerve activity by electrically stimulating a specific nerve. For people who have not responded to anti-seizure medicine and intense depression treatments, including electroconvulsive therapy, psychotherapy, and antidepressants, an implantable VNS device may be useful (ECT). Furthermore, the demand for and uptake of VNS devices in the global market is fueled by the launch of new and innovative products by major industry competitors.

Metallic Category Leads Vagus Nerve Stimulation Market with Expansion in Research and Development for Medicines

The metallic category dominated the vagus nerve stimulation market in 2021 due to improvements and expansion in research and development for medicines involving vagus nerve stimulation. Through 2030, the category is anticipated to remain in its current position. Due to their thermal conductivity & mechanical qualities, metallic biomaterials are most frequently employed in medical devices such as implanted devices. Some of the metals utilized for coating electrical implanted devices because of their anti-inflammatory qualities include 316L stainless steel, titanium-based alloys, gold, tantalum, silver, platinum, and cobalt-chromium alloys. Besides, the polymeric category is anticipated to grow significantly over the forecast period. Stress, and despair are becoming more commonplace all around the world. Polymers can regenerate injured brain tissues and be formed into scaffolds, electro-spun matrices, nerve conduits, and other support structures.

North America to Dominate Vagus Nerve Stimulation Market Owing to Rise in Government Financing

Over the forecast period, it is anticipated that North American market will account for the largest revenue share owing to a rise in government financing and programs to expand knowledge about epilepsy and challenging-to-treat depression in the area. Many other important factors, including quick technological development, the presence of important manufacturers in the area, an increase in R&D expenditures, and an increase in government funding and initiatives, are anticipated to generate significant growth opportunities in the vagus nerve stimulation market. For instance, the Centers for Medicare & Medicaid Services (CMS) estimates that U.S. health spending will increase by 5.5% annually between 2018 and 2027 and total US$6 Tn by that year. In addition, the high level of disposable income in advanced nations and the accessibility of qualified specialists are further variables that contribute to the North American region's dominant market share.

The Asia Pacific vagus nerve stimulation market is anticipated to experience stable revenue growth throughout the forecast period. It is explained by the region's increasing frequency of neurodegenerative diseases and the unmet need for long-lasting remedies. Market expansion in this region is anticipated to be fueled by increasing consumer knowledge of available treatments for neurological diseases and advancements in emerging economies' clinical development frameworks. Additionally, high-growth potential in developing nations like Japan, China, and India will probably support market expansion. Furthermore, it is hoped that creating institutions like the Asia Pacific Centre for Neuromodulation (APCN), which was formed to conduct research and raise awareness about the benefits of vagus nerve stimulation, will promote regional growth.

Global Vagus Nerve Stimulation Market: Competitive Landscape

In May 2022, the gammaCore Sapphire non-invasive Vagus Nerve Stimulator will be offered to patients experiencing pain related to several primary headache types in 130 National Spine and Pain Centers (NSPC) affiliated locations across the United States, according to an announcement by electroCore, Inc. It would assist the company in generating more income. Similarly, in June 2019, IB-Stim, a product manufactured by Innovative Health Solutions Inc., a US-based company, received the US FDA approval to help children with irritable bowel syndrome between the ages of 11 and 18 with their gastrointestinal pain (IBS).

A few of the vagus nerve stimulation market players are:

• LivaNova PLC
• ElectroCore, Inc.
• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• NeuroSigma, Inc.
• SetPoint Medical
• Soterix Medical Inc.
• tVNS Technologies GmbH
• Cerebral Therapeutics, Inc.
• Parasym Ltd.
• Aleva Neurotherapeutics SA
• Neuralace Medical, Inc.
• NeuroMetrix, Inc.
• Nervomatrix 

Global Vagus Nerve Stimulation Market is Segmented as Below:  

By Product
• Implantable VNS Device
• External Non-invasive VNS Device 

By Application
• Epilepsy
• Depression
• Migraine
• Others 

By End-user
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centres
• Academic & Research Institutes
• Others

By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa